Full metadata record
|dc.identifier.citation||VOL 36, NO 2, 527-533||-|
|dc.description.abstract||In the present study, the anti-diabetic effects of amorphastilbol (APH) from Amorpha fruticosa (AF) were evaluated in high-fat-diet (HFD) mice. HFD-induced blood glucose and insulin levels are significantly reduced in AF extract or APH treatment groups. HFD-induced weight gain was reduced by AF treatment, which is accompanied by reduction of fat mass and adipocyte size and number in white adipose tissues. Furthermore, total cholesterol and low-density lipoprotein-cholesterol levels are decreased in AF- or APH-treated mice. In addition, AF and APH are able to improve insulin sensitivity through inhibition of protein tyrosine phosphatase 1B, a negative regulator of the insulin-signaling pathway. Taken together, the data suggest that AF has beneficial effects on glucose and lipid metabolism and its pharmacological effects are driven, in part, by its active component, APH. Therefore, AF and APH can be used as potential therapeutic agents against type 2 diabetes and associated metabolic disorders, including obesity, by enhancing glucose and lipid metabolism.||-|
|dc.publisher||International journal of molecular medicine||-|
|dc.subject||PPAR a/r dual agonist||-|
|dc.title||Amorphastilbol exerts beneficial effects on glucose and lipid metabolism in mice consuming a high-fat-diet.||-|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.